Search

First CMML guidelines produced by EHA, now available

Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.

Read more

Can Eltrombopag help children with ITP say goodbye to bleeding?

 

Immune thrombocytopenia (ITP) is a rare disease in children, affecting 5 in 100,000. Most children get better quickly without intervention but up to 30% will still have disease at 12 months.

Read more

Press release: 18th Congress of the European Hematology Association in Stockholm, Sweden June 13-16-2013

The EHA-theme of the year, from June 2013 to June 2014, is dedicated to “Age and Aging in blood disorders”.

Read more

TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS

Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.

Read more

The February 2018 - Volume 2 - Issue 1 of HemaSphere is now available online

The February 2018 - Volume 2 - Issue 1 of HemaSphere is now available online. HemaSphere is an open access journal, powered by the European Hematology Association and dedicated to support hematology patient care, research and education worldwide.

Read more

EHA-ISHBT Hematology Tutorial

Date: March 1-3, 2024
Format: In-Person
Location: Hyderabad, India

Chairs: P. K.

Read more

The European Parliament adopts the Regulation on Substances of Human Origins (SoHO)

On April 24, the European Parliament gave its final endorsement to the regulation on Substances of Human Origin (SoHO).

Read more

Two genes cooperate to trigger leukemia development

Congratulations to the international group of researchers led by HemaSphere Editor-in-Chief Prof.

Read more

About us

The European Hematology Association (EHA): “Towards prevention, cure, and quality of life for all patients with blood disorders”.

Read more